The National Agency for Food and Drug Administration and Control (NAFDAC) has halted  the registration of Multi-Dose Anti-Malarial (Artemether/Lumefantrine) dry powder for oral suspension. The announcement was made in a public alert No. 01/2025, released on the agency’s website yesterday. NAFDAC explained that the decision was made due to the instability of the reconstituted formulations, which could lead to a loss of efficacy over time. According NAFDAC, the suspension applies to all locally manufactured and imported Multi-Dose Artemether/Lumefantrine dry powder for oral use. “NAFDAC will no longer accept new applications, renewals, or variations for this product.” According to the Agency,…